Experiments in social responsibility

Pursuing drugs for neglected diseases is not a traditional part of the pharmaceutical company portfolio. But Paul Herrling of Novartis finds that it brings welcome changes both within and outside the industry. Adopt a disease The Novartis research facility in Singapore, focusing on dengue fever and...

Full description

Saved in:
Bibliographic Details
Published in:Nature 2006-01, Vol.439 (7074), p.267-268
Main Author: Herrling, Paul
Format: Article
Language:English
Subjects:
Bioethics
Charities - economics
Charities - trends
commentary
Corporate social responsibility
Dengue - drug therapy
Dengue fever
Developing Countries
Disease
Drug Industry - economics
Drug Industry - trends
Drug therapy
Drugs
Global Health
Humanities and Social Sciences
Humans
LDCs
multidisciplinary
NGOs
Nongovernmental organizations
Orphan drugs
Patents as Topic
Pharmaceutical industry
Planning
Product development
Science
Science (multidisciplinary)
Social responsibility
Tuberculosis
Tuberculosis - drug therapy
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pursuing drugs for neglected diseases is not a traditional part of the pharmaceutical company portfolio. But Paul Herrling of Novartis finds that it brings welcome changes both within and outside the industry. Adopt a disease The Novartis research facility in Singapore, focusing on dengue fever and tuberculosis, reflects a new approach from pharmaceuticals companies keen to show their soft side. Market forces have failed to generate the research needed for the development of drugs to treat rare or ‘orphan’ diseases in developing countries. In a Commentary, Novartis's head of corporate research argues that a new culture is emerging throughout the industry that recognizes a need to temper the commercial imperative with a social approach to developing drugs that will not generate high profits.
ISSN:0028-0836
1476-4687
DOI:10.1038/439267a